Home > Boards > US Listed > Biotechs > Ionis Pharmaceuticals Inc. (IONS)

The advisory committee recommended approval. A very small

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jimmy667 Member Profile
 
Followed By 85
Posts 5,163
Boards Moderated 0
Alias Born 10/20/15
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/18/2021 2:31:51 PM
Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint Dow Jones News - 10/18/2021 10:55:00 AM
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS PR Newswire (US) - 10/17/2021 4:20:00 PM
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting GlobeNewswire Inc. - 10/14/2021 4:06:00 PM
VC Daily: Expansion Therapeutics Gets $80 Million for RNA-Targeted Drugs Dow Jones News - 9/30/2021 10:54:00 AM
PTC Therapeutics slips after early stage results from Huntington's disease trial Seeking Alpha - 9/23/2021 3:34:23 PM
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam) GlobeNewswire Inc. - 9/15/2021 7:30:00 AM
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting PR Newswire (US) - 9/3/2021 7:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 7:26:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 7:21:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 7:21:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 7:21:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 7:21:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2021 7:20:54 PM
Ionis to present at upcoming virtual investor conferences PR Newswire (US) - 9/2/2021 7:05:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/5/2021 5:00:08 PM
Ionis Pharmaceuticals EPS in-line, misses on revenue Seeking Alpha - 8/4/2021 7:04:07 AM
Ionis reports second quarter 2021 financial results and recent business achievements PR Newswire (US) - 8/4/2021 7:00:00 AM
Ionis provides enrollment update for Novartis' late-stage pelacarsen study Seeking Alpha - 8/2/2021 10:14:13 AM
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events PR Newswire (US) - 8/2/2021 9:30:00 AM
Ionis completes enrollment in late-stage eplontersen polyneuropathy study Seeking Alpha - 7/29/2021 7:47:31 AM
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen PR Newswire (US) - 7/29/2021 7:05:00 AM
Biogen and Ionis post promising data from early-stage BIIB080 Alzheimer's disease trial Seeking Alpha - 7/26/2021 5:01:36 PM
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC PR Newswire (US) - 7/26/2021 4:35:00 PM
Ionis to hold second quarter 2021 financial results webcast PR Newswire (US) - 7/21/2021 7:05:00 AM
jimmy667   Monday, 08/27/18 09:54:56 PM
Re: shub post# 476
Post # of 485 
The advisory committee recommended approval. A very small number of patents with deadly disease with no other options and the FDA issued a CRL instead of approval. Patients die short sellers get rich. What is wrong with the FDA? Corruption? Or is the Anti-sense platform a fraud? Get a rope. But who should be strung up IONS or the FDA? Right now it is the patients and long stock holders feeling the pain.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences